These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
329 related articles for article (PubMed ID: 2721567)
1. A new potent and selective non-peptide gastrin antagonist and brain cholecystokinin receptor (CCK-B) ligand: L-365,260. Lotti VJ; Chang RS Eur J Pharmacol; 1989 Mar; 162(2):273-80. PubMed ID: 2721567 [TBL] [Abstract][Full Text] [Related]
2. Pharmacological profile of (R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo- 5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo. Nishida A; Miyata K; Tsutsumi R; Yuki H; Akuzawa S; Kobayashi A; Kamato T; Ito H; Yamano M; Katuyama Y J Pharmacol Exp Ther; 1994 May; 269(2):725-31. PubMed ID: 7910212 [TBL] [Abstract][Full Text] [Related]
3. (3R)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl)-N'-(3-(methylamino)phenyl)urea (YF476): a potent and orally active gastrin/CCK-B antagonist. Semple G; Ryder H; Rooker DP; Batt AR; Kendrick DA; Szelke M; Ohta M; Satoh M; Nishida A; Akuzawa S; Miyata K J Med Chem; 1997 Jan; 40(3):331-41. PubMed ID: 9022799 [TBL] [Abstract][Full Text] [Related]
4. Characterization of antisecretory and antiulcer activity of CR 2945, a new potent and selective gastrin/CCK(B) receptor antagonist. Makovec F; Revel L; Letari O; Mennuni L; Impicciatore M Eur J Pharmacol; 1999 Mar; 369(1):81-90. PubMed ID: 10204685 [TBL] [Abstract][Full Text] [Related]
5. Characterization of the binding of [3H]L-365,260: a new potent and selective brain cholecystokinin (CCK-B) and gastrin receptor antagonist radioligand. Chang RS; Chen TB; Bock MG; Freidinger RM; Chen R; Rosegay A; Lotti VJ Mol Pharmacol; 1989 Jun; 35(6):803-8. PubMed ID: 2733696 [TBL] [Abstract][Full Text] [Related]
6. Biological properties of the benzodiazepine amidine derivative L-740,093, a cholecystokinin-B/gastrin receptor antagonist with high affinity in vitro and high potency in vivo. Patel S; Smith AJ; Chapman KL; Fletcher AE; Kemp JA; Marshall GR; Hargreaves RJ; Ryecroft W; Iversen LL; Iversen SD Mol Pharmacol; 1994 Nov; 46(5):943-8. PubMed ID: 7969084 [TBL] [Abstract][Full Text] [Related]
7. YF476 is a new potent and selective gastrin/cholecystokinin-B receptor antagonist in vitro and in vivo. Takinami Y; Yuki H; Nishida A; Akuzawa S; Uchida A; Takemoto Y; Ohta M; Satoh M; Semple G; Miyata K Aliment Pharmacol Ther; 1997 Feb; 11(1):113-20. PubMed ID: 9042983 [TBL] [Abstract][Full Text] [Related]
8. Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist. Chang RS; Lotti VJ Proc Natl Acad Sci U S A; 1986 Jul; 83(13):4923-6. PubMed ID: 3014520 [TBL] [Abstract][Full Text] [Related]
9. Characterization of CCK receptors in a novel smooth muscle preparation from the guinea-pig stomach by use of the selective antagonists CI-988, L-365,260 and devazepide. Boyle SJ; Tang KW; Woodruff GN; McKnight AT Br J Pharmacol; 1993 Aug; 109(4):913-7. PubMed ID: 8401944 [TBL] [Abstract][Full Text] [Related]